Key result
Osimertinib pooled phase III analysis characterizes cardiac toxicity rates in advanced NSCLC.
Why the study?
Although osimertinib improves survival in advanced non-small-cell lung cancer with EGFR mutations, cardiac toxicities remain a safety concern and their incidence required evaluation.
Meta-Analysis
May warrant enhanced cardiac surveillance with osimertinib; extends RCT incidence data to inform monitoring and future trials.
Background: Osimertinib is an oral, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). In both EGFR-TKI sensitizing and EGFR T790M resistance mutations in advanced non-small-cell lung cancer (NSCLC), osimertinib has shown to improve survival. Nevertheless, cardiac toxicities remain a safety concern. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the incidence of cardiac toxicities.
No takes yet. Share an insight, caveat, or question.
Thein et al. (2018) conducted a meta-analysis in Advanced non-small-cell lung cancer (NSCLC). Osimertinib was evaluated on Incidence of cardiac toxicities. Osimertinib was evaluated in a combined analysis of two phase III randomized controlled trials to determine the incidence of cardiac toxicities in advanced NSCLC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: